Lv52
1090 积分 2021-08-09 加入
Why does GLP‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP‐1 agonist alone in obese adults without type 2 diabetes?
23天前
已完结
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
29天前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
1个月前
已完结
Real‐world retrospective study in elderly patients aged 65 years and older with type 2 diabetes mellitus treated with daily oral semaglutide (SEMA‐elderly)
1个月前
已完结
Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review
1个月前
已完结
Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO)
1个月前
已完结
Prevalence of Chronic Kidney Disease in China
2个月前
已完结
The global burden of early-onset type 2 diabetes mellitus caused by high body-mass index from 1990 to 2021 and projection to 2050
4个月前
已完结
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
5个月前
已完结
Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study
6个月前
已完结
Bmal1 is involved in the regulation of macrophage cholesterol homeostasis
皖公网安备34019202002308
